Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in pediatric Crohn's disease
2024-511472-32-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised trial of mirikizumab in Crohn's disease (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Clinical response at Week 12 and endoscopic response at Week 52 and Clinical response at Week 12 and clinical remission at Week 52. Planned start Mar 2024; status: authorised.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-511472-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511472-32-00.